Maralixibat Study Now Recruiting Patients With ALGS Under 12 Months of Age
A new open-label, phase 2 study set to evaluate the safety and tolerability of maralixibat in infants with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis is currently recruiting infants under 12 months of age. Following the US Food and Drug Administration (FDA) approval of maralixibat for the treatment of cholestatic pruritus in patients with ALGS…